Knee pain injection on trial15th January 2008
Trials are beginning in the United States of a single-injection treatment which could bring benefits to osteaoarthritis sufferers.
The company that makes the drug, Anika Therapeutics, said it was beginning trials for its hyaluronic acid-based compound.
In the randomised, double-blind, controlled trials, the company hopes to demonstrate that a single injection of the drug can provide safe relief to those who suffer knee pain and dysfunction as a result of osteoarthritis.
Hyaluronic acid is a natural component of synovial fluid that lubricates joints and has been found in some trials to relieve the pain of knee osteoarthritis. Hyaluronic acid products are already on the market, but usually administered in a course of three to five injections.
Anika has enrolled its first patient in a multi-center study evaluating its single-injection osteoarthritis product, Monovisc.
The company said it was a key step towards the commercialisation of the drug in the US market.
Anika received European CE Mark approval for Monovisc in September 2007 and expects to launch the product in Europe in the first half of 2008.
Anika's CEO, Charles Sherwood, said the therapy would be more convenient for doctors and patients.
Arthritis campaigners say hyaluronic acid seems to help some patients with osteoarthritis of the knee, but not others, and say scientific evidence for its efficacy is mixed.
Anika Therapeutics develops, manufactures and commercialises therapeutic products and devices intended to promote the repair, protection and healing of bone, cartilage and soft tissue.
These products are based on hyaluronic acid (HA), a naturally occurring, biocompatible polymer found throughout the body.
Share this page
There are no comments for this article, be the first to comment!
Post your comment
Only registered users can comment. Fill in your e-mail address for quick registration.
Title: Knee pain injection on trial
Author: Luisetta Mudie
Article Id: 5318
Date Added: 15th Jan 2008